title: Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
authors.affiliation: Eli Lilly and Company, Suresnes, France kazda_christof@lilly.com.
authors.forename: Christof M
authors.initials: CM
authors.lastname: Kazda
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Ying
authors.initials: Y
authors.lastname: Ding
authors.affiliation: Lilly-NUS Centre for Clinical Pharmacology, Singapore.
authors.forename: Ronan P
authors.initials: RP
authors.lastname: Kelly
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Parag
authors.initials: P
authors.lastname: Garhyan
authors.affiliation: inVentiv Health Clinical, Clarksville, MD.
authors.forename: Chunxue
authors.initials: C
authors.lastname: Shi
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Chay Ngee
authors.initials: CN
authors.lastname: Lim
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Haoda
authors.initials: H
authors.lastname: Fu
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: David E
authors.initials: DE
authors.lastname: Watson
authors.affiliation: National Research Institute, Los Angeles, CA.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Lewin
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: William H
authors.initials: WH
authors.lastname: Landschulz
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Deeg
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: David E
authors.initials: DE
authors.lastname: Moller
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Hardy
mesh_terms: D001713:Biphenyl Compounds; D003924:Diabetes Mellitus, Type 2; D005934:Glucagon; D006801:Humans; D018027:Receptors, Glucagon / Q000037:antagonists & inhibitors*
chemical_list: D001713:Biphenyl Compounds; D018027:Receptors, Glucagon; C000601762:adomeglivant; D005934:Glucagon